Released Mar 21, 2024, before the open
10-K filed Mar 21, 2024, 81 days after period end · 0001171843-24-001516
Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$13.42M-$13.42M derivedN/M vs Q4 2022N/M vs Q3 2023
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$15,389,000N/M
Operating Cash Flowderived-$12,354,000N/M
Free Cash Flowderived-$12,363,000N/M
What the release said
The release
Same quarter
| Metric | Q4 2023dderived from reported figures | Q4 2022dderived from reported figures | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures |
|---|---|---|---|---|
| Net Income | -$13.42M | -$11.59M | -$12.98M | -$8.39M |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR